nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—CYP2D6—Carteolol—glaucoma	0.055	0.154	CbGbCtD
Ponatinib—CYP2D6—Betaxolol—glaucoma	0.0371	0.104	CbGbCtD
Ponatinib—CYP3A5—Clonidine—glaucoma	0.0332	0.0929	CbGbCtD
Ponatinib—CYP2D6—Methazolamide—glaucoma	0.0281	0.0788	CbGbCtD
Ponatinib—CYP3A4—Pilocarpine—glaucoma	0.0265	0.0742	CbGbCtD
Ponatinib—ABCB1—Timolol—glaucoma	0.0254	0.0711	CbGbCtD
Ponatinib—CYP2D6—Timolol—glaucoma	0.0239	0.067	CbGbCtD
Ponatinib—ABCB1—Clonidine—glaucoma	0.0216	0.0605	CbGbCtD
Ponatinib—CYP3A4—Brinzolamide—glaucoma	0.0208	0.0582	CbGbCtD
Ponatinib—CYP2D6—Clonidine—glaucoma	0.0204	0.057	CbGbCtD
Ponatinib—CYP3A4—Dorzolamide—glaucoma	0.0201	0.0562	CbGbCtD
Ponatinib—CYP3A4—Methazolamide—glaucoma	0.0179	0.0501	CbGbCtD
Ponatinib—FGFR2—cornea—glaucoma	0.0177	0.234	CbGeAlD
Ponatinib—CYP3A4—Acetazolamide—glaucoma	0.0143	0.0401	CbGbCtD
Ponatinib—CYP3A4—Clonidine—glaucoma	0.0129	0.0362	CbGbCtD
Ponatinib—FGFR4—connective tissue—glaucoma	0.0047	0.0621	CbGeAlD
Ponatinib—TEK—endothelium—glaucoma	0.00426	0.0563	CbGeAlD
Ponatinib—SRC—endothelium—glaucoma	0.00378	0.05	CbGeAlD
Ponatinib—KDR—endothelium—glaucoma	0.00348	0.046	CbGeAlD
Ponatinib—LYN—connective tissue—glaucoma	0.00322	0.0426	CbGeAlD
Ponatinib—FGFR3—connective tissue—glaucoma	0.00321	0.0424	CbGeAlD
Ponatinib—KIT—endothelium—glaucoma	0.00308	0.0407	CbGeAlD
Ponatinib—BCR—eye—glaucoma	0.00288	0.0381	CbGeAlD
Ponatinib—Imatinib—NTRK1—glaucoma	0.00279	0.272	CrCbGaD
Ponatinib—FLT3—connective tissue—glaucoma	0.00275	0.0364	CbGeAlD
Ponatinib—Nilotinib—CA1—glaucoma	0.00232	0.226	CrCbGaD
Ponatinib—RET—connective tissue—glaucoma	0.00221	0.0292	CbGeAlD
Ponatinib—FGFR2—eye—glaucoma	0.00218	0.0288	CbGeAlD
Ponatinib—FGFR2—connective tissue—glaucoma	0.0021	0.0277	CbGeAlD
Ponatinib—TEK—connective tissue—glaucoma	0.00201	0.0266	CbGeAlD
Ponatinib—Imatinib—CA1—glaucoma	0.00194	0.188	CrCbGaD
Ponatinib—SRC—eye—glaucoma	0.00186	0.0245	CbGeAlD
Ponatinib—SRC—retina—glaucoma	0.00184	0.0243	CbGeAlD
Ponatinib—PDGFRA—connective tissue—glaucoma	0.00182	0.0241	CbGeAlD
Ponatinib—SRC—connective tissue—glaucoma	0.00179	0.0236	CbGeAlD
Ponatinib—Nilotinib—CA2—glaucoma	0.00176	0.171	CrCbGaD
Ponatinib—KDR—eye—glaucoma	0.00171	0.0226	CbGeAlD
Ponatinib—KDR—retina—glaucoma	0.00169	0.0224	CbGeAlD
Ponatinib—KDR—connective tissue—glaucoma	0.00164	0.0217	CbGeAlD
Ponatinib—Imatinib—CA2—glaucoma	0.00147	0.143	CrCbGaD
Ponatinib—KIT—connective tissue—glaucoma	0.00146	0.0193	CbGeAlD
Ponatinib—ABL1—eye—glaucoma	0.00132	0.0174	CbGeAlD
Ponatinib—ABL1—retina—glaucoma	0.00131	0.0173	CbGeAlD
Ponatinib—ABL1—connective tissue—glaucoma	0.00127	0.0168	CbGeAlD
Ponatinib—ABCB1—retina—glaucoma	0.000406	0.00536	CbGeAlD
Ponatinib—Fatigue—Acetazolamide—glaucoma	0.000306	0.00102	CcSEcCtD
Ponatinib—Paraesthesia—Brimonidine—glaucoma	0.000306	0.00101	CcSEcCtD
Ponatinib—Infection—Pilocarpine—glaucoma	0.000305	0.00101	CcSEcCtD
Ponatinib—Alopecia—Clonidine—glaucoma	0.000305	0.00101	CcSEcCtD
Ponatinib—Nausea—Methazolamide—glaucoma	0.000304	0.00101	CcSEcCtD
Ponatinib—Dyspnoea—Brimonidine—glaucoma	0.000304	0.00101	CcSEcCtD
Ponatinib—Mental disorder—Clonidine—glaucoma	0.000303	0.001	CcSEcCtD
Ponatinib—Thrombocytopenia—Pilocarpine—glaucoma	0.000301	0.000999	CcSEcCtD
Ponatinib—Erythema—Clonidine—glaucoma	0.000301	0.000998	CcSEcCtD
Ponatinib—Dyspepsia—Brimonidine—glaucoma	0.0003	0.000995	CcSEcCtD
Ponatinib—Hypoaesthesia—Betaxolol—glaucoma	0.000299	0.000993	CcSEcCtD
Ponatinib—Angina pectoris—Timolol—glaucoma	0.000299	0.000992	CcSEcCtD
Ponatinib—Hyperhidrosis—Pilocarpine—glaucoma	0.000297	0.000986	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000296	0.000983	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Travoprost—glaucoma	0.000295	0.000979	CcSEcCtD
Ponatinib—Insomnia—Dorzolamide—glaucoma	0.000294	0.000976	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000294	0.000976	CcSEcCtD
Ponatinib—Fatigue—Brimonidine—glaucoma	0.000294	0.000974	CcSEcCtD
Ponatinib—Paraesthesia—Dorzolamide—glaucoma	0.000292	0.000969	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000291	0.000967	CcSEcCtD
Ponatinib—Pain—Brimonidine—glaucoma	0.000291	0.000966	CcSEcCtD
Ponatinib—Dyspnoea—Dorzolamide—glaucoma	0.00029	0.000962	CcSEcCtD
Ponatinib—Visual impairment—Betaxolol—glaucoma	0.00029	0.000962	CcSEcCtD
Ponatinib—Insomnia—Brinzolamide—glaucoma	0.000289	0.00096	CcSEcCtD
Ponatinib—Muscle spasms—Clonidine—glaucoma	0.000289	0.000959	CcSEcCtD
Ponatinib—Dyspnoea—Travoprost—glaucoma	0.000289	0.000958	CcSEcCtD
Ponatinib—Paraesthesia—Brinzolamide—glaucoma	0.000287	0.000953	CcSEcCtD
Ponatinib—Dyspepsia—Dorzolamide—glaucoma	0.000286	0.00095	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Timolol—glaucoma	0.000285	0.000947	CcSEcCtD
Ponatinib—Dyspnoea—Brinzolamide—glaucoma	0.000285	0.000946	CcSEcCtD
Ponatinib—Dyspepsia—Travoprost—glaucoma	0.000285	0.000946	CcSEcCtD
Ponatinib—Asthenia—Apraclonidine—glaucoma	0.000285	0.000944	CcSEcCtD
Ponatinib—Vision blurred—Clonidine—glaucoma	0.000283	0.00094	CcSEcCtD
Ponatinib—Decreased appetite—Dorzolamide—glaucoma	0.000283	0.000938	CcSEcCtD
Ponatinib—Erectile dysfunction—Timolol—glaucoma	0.000283	0.000938	CcSEcCtD
Ponatinib—Dyspepsia—Brinzolamide—glaucoma	0.000281	0.000934	CcSEcCtD
Ponatinib—Eye disorder—Betaxolol—glaucoma	0.000281	0.000933	CcSEcCtD
Ponatinib—Pruritus—Apraclonidine—glaucoma	0.000281	0.000931	CcSEcCtD
Ponatinib—Body temperature increased—Acetazolamide—glaucoma	0.00028	0.000931	CcSEcCtD
Ponatinib—Fatigue—Dorzolamide—glaucoma	0.00028	0.000931	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00028	0.000929	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Travoprost—glaucoma	0.000279	0.000928	CcSEcCtD
Ponatinib—Fatigue—Travoprost—glaucoma	0.000279	0.000927	CcSEcCtD
Ponatinib—Cardiac disorder—Betaxolol—glaucoma	0.000279	0.000926	CcSEcCtD
Ponatinib—Flushing—Betaxolol—glaucoma	0.000279	0.000926	CcSEcCtD
Ponatinib—Pain—Dorzolamide—glaucoma	0.000278	0.000923	CcSEcCtD
Ponatinib—Insomnia—Pilocarpine—glaucoma	0.000278	0.000922	CcSEcCtD
Ponatinib—Decreased appetite—Brinzolamide—glaucoma	0.000278	0.000922	CcSEcCtD
Ponatinib—Weight decreased—Timolol—glaucoma	0.000278	0.000922	CcSEcCtD
Ponatinib—Pain—Travoprost—glaucoma	0.000277	0.000919	CcSEcCtD
Ponatinib—Constipation—Travoprost—glaucoma	0.000277	0.000919	CcSEcCtD
Ponatinib—Hyperglycaemia—Timolol—glaucoma	0.000277	0.000919	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000276	0.000916	CcSEcCtD
Ponatinib—Paraesthesia—Pilocarpine—glaucoma	0.000276	0.000916	CcSEcCtD
Ponatinib—Asthenia—Bimatoprost—glaucoma	0.000276	0.000916	CcSEcCtD
Ponatinib—Fatigue—Brinzolamide—glaucoma	0.000276	0.000915	CcSEcCtD
Ponatinib—Dyspnoea—Pilocarpine—glaucoma	0.000274	0.000909	CcSEcCtD
Ponatinib—Pain—Brinzolamide—glaucoma	0.000273	0.000907	CcSEcCtD
Ponatinib—Angiopathy—Betaxolol—glaucoma	0.000273	0.000906	CcSEcCtD
Ponatinib—Pruritus—Bimatoprost—glaucoma	0.000272	0.000903	CcSEcCtD
Ponatinib—Diarrhoea—Apraclonidine—glaucoma	0.000271	0.000901	CcSEcCtD
Ponatinib—Mediastinal disorder—Betaxolol—glaucoma	0.000271	0.000899	CcSEcCtD
Ponatinib—Dyspepsia—Pilocarpine—glaucoma	0.00027	0.000898	CcSEcCtD
Ponatinib—Chills—Betaxolol—glaucoma	0.00027	0.000896	CcSEcCtD
Ponatinib—Arrhythmia—Betaxolol—glaucoma	0.000269	0.000892	CcSEcCtD
Ponatinib—Decreased appetite—Pilocarpine—glaucoma	0.000267	0.000887	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000266	0.000883	CcSEcCtD
Ponatinib—Alopecia—Betaxolol—glaucoma	0.000266	0.000882	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000265	0.00088	CcSEcCtD
Ponatinib—Gastrointestinal pain—Travoprost—glaucoma	0.000265	0.000879	CcSEcCtD
Ponatinib—Mental disorder—Betaxolol—glaucoma	0.000263	0.000874	CcSEcCtD
Ponatinib—Pain—Pilocarpine—glaucoma	0.000263	0.000872	CcSEcCtD
Ponatinib—Constipation—Pilocarpine—glaucoma	0.000263	0.000872	CcSEcCtD
Ponatinib—Cough—Clonidine—glaucoma	0.000262	0.000871	CcSEcCtD
Ponatinib—Dizziness—Apraclonidine—glaucoma	0.000262	0.000871	CcSEcCtD
Ponatinib—Malnutrition—Betaxolol—glaucoma	0.000262	0.000869	CcSEcCtD
Ponatinib—Erythema—Betaxolol—glaucoma	0.000262	0.000869	CcSEcCtD
Ponatinib—Epistaxis—Timolol—glaucoma	0.000258	0.000857	CcSEcCtD
Ponatinib—Abdominal pain—Dorzolamide—glaucoma	0.000257	0.000853	CcSEcCtD
Ponatinib—Body temperature increased—Dorzolamide—glaucoma	0.000257	0.000853	CcSEcCtD
Ponatinib—Arthralgia—Clonidine—glaucoma	0.000256	0.00085	CcSEcCtD
Ponatinib—Abdominal pain—Travoprost—glaucoma	0.000256	0.00085	CcSEcCtD
Ponatinib—Asthenia—Acetazolamide—glaucoma	0.000254	0.000845	CcSEcCtD
Ponatinib—Dizziness—Bimatoprost—glaucoma	0.000254	0.000844	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000254	0.000844	CcSEcCtD
Ponatinib—Vomiting—Apraclonidine—glaucoma	0.000252	0.000837	CcSEcCtD
Ponatinib—Muscle spasms—Betaxolol—glaucoma	0.000252	0.000835	CcSEcCtD
Ponatinib—Gastrointestinal pain—Pilocarpine—glaucoma	0.000251	0.000834	CcSEcCtD
Ponatinib—Dry mouth—Clonidine—glaucoma	0.00025	0.000831	CcSEcCtD
Ponatinib—Dermatitis—Apraclonidine—glaucoma	0.00025	0.000829	CcSEcCtD
Ponatinib—Headache—Apraclonidine—glaucoma	0.000248	0.000825	CcSEcCtD
Ponatinib—Vision blurred—Betaxolol—glaucoma	0.000247	0.000819	CcSEcCtD
Ponatinib—Oedema—Clonidine—glaucoma	0.000245	0.000814	CcSEcCtD
Ponatinib—Asthenia—Brimonidine—glaucoma	0.000244	0.000811	CcSEcCtD
Ponatinib—Infection—Clonidine—glaucoma	0.000244	0.000809	CcSEcCtD
Ponatinib—Abdominal pain—Pilocarpine—glaucoma	0.000243	0.000806	CcSEcCtD
Ponatinib—Body temperature increased—Pilocarpine—glaucoma	0.000243	0.000806	CcSEcCtD
Ponatinib—Diarrhoea—Acetazolamide—glaucoma	0.000243	0.000806	CcSEcCtD
Ponatinib—Rash—Bimatoprost—glaucoma	0.000242	0.000805	CcSEcCtD
Ponatinib—Dermatitis—Bimatoprost—glaucoma	0.000242	0.000804	CcSEcCtD
Ponatinib—Oedema peripheral—Timolol—glaucoma	0.000242	0.000803	CcSEcCtD
Ponatinib—Anaemia—Betaxolol—glaucoma	0.000242	0.000803	CcSEcCtD
Ponatinib—Connective tissue disorder—Timolol—glaucoma	0.000241	0.000801	CcSEcCtD
Ponatinib—Pruritus—Brimonidine—glaucoma	0.000241	0.0008	CcSEcCtD
Ponatinib—Headache—Bimatoprost—glaucoma	0.000241	0.0008	CcSEcCtD
Ponatinib—Nervous system disorder—Clonidine—glaucoma	0.000241	0.000799	CcSEcCtD
Ponatinib—Thrombocytopenia—Clonidine—glaucoma	0.00024	0.000797	CcSEcCtD
Ponatinib—Skin disorder—Clonidine—glaucoma	0.000238	0.000791	CcSEcCtD
Ponatinib—Hyperhidrosis—Clonidine—glaucoma	0.000237	0.000787	CcSEcCtD
Ponatinib—Visual impairment—Timolol—glaucoma	0.000237	0.000786	CcSEcCtD
Ponatinib—Nausea—Apraclonidine—glaucoma	0.000236	0.000782	CcSEcCtD
Ponatinib—Dizziness—Acetazolamide—glaucoma	0.000235	0.000779	CcSEcCtD
Ponatinib—Asthenia—Dorzolamide—glaucoma	0.000233	0.000774	CcSEcCtD
Ponatinib—Asthenia—Travoprost—glaucoma	0.000232	0.000771	CcSEcCtD
Ponatinib—Pruritus—Dorzolamide—glaucoma	0.00023	0.000764	CcSEcCtD
Ponatinib—Eye disorder—Timolol—glaucoma	0.00023	0.000762	CcSEcCtD
Ponatinib—Asthenia—Brinzolamide—glaucoma	0.000229	0.000761	CcSEcCtD
Ponatinib—Pruritus—Travoprost—glaucoma	0.000229	0.00076	CcSEcCtD
Ponatinib—Cough—Betaxolol—glaucoma	0.000228	0.000758	CcSEcCtD
Ponatinib—Nausea—Bimatoprost—glaucoma	0.000228	0.000758	CcSEcCtD
Ponatinib—Cardiac disorder—Timolol—glaucoma	0.000228	0.000757	CcSEcCtD
Ponatinib—Pruritus—Brinzolamide—glaucoma	0.000226	0.000751	CcSEcCtD
Ponatinib—Vomiting—Acetazolamide—glaucoma	0.000226	0.000749	CcSEcCtD
Ponatinib—Dizziness—Brimonidine—glaucoma	0.000225	0.000747	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Clonidine—glaucoma	0.000224	0.000742	CcSEcCtD
Ponatinib—Angiopathy—Timolol—glaucoma	0.000223	0.00074	CcSEcCtD
Ponatinib—Myalgia—Betaxolol—glaucoma	0.000223	0.00074	CcSEcCtD
Ponatinib—Arthralgia—Betaxolol—glaucoma	0.000223	0.00074	CcSEcCtD
Ponatinib—Diarrhoea—Dorzolamide—glaucoma	0.000222	0.000738	CcSEcCtD
Ponatinib—Headache—Acetazolamide—glaucoma	0.000222	0.000738	CcSEcCtD
Ponatinib—Insomnia—Clonidine—glaucoma	0.000222	0.000737	CcSEcCtD
Ponatinib—Diarrhoea—Travoprost—glaucoma	0.000221	0.000735	CcSEcCtD
Ponatinib—Mediastinal disorder—Timolol—glaucoma	0.000221	0.000735	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000221	0.000735	CcSEcCtD
Ponatinib—Asthenia—Pilocarpine—glaucoma	0.00022	0.000732	CcSEcCtD
Ponatinib—Paraesthesia—Clonidine—glaucoma	0.00022	0.000731	CcSEcCtD
Ponatinib—Arrhythmia—Timolol—glaucoma	0.000219	0.000728	CcSEcCtD
Ponatinib—Dyspnoea—Clonidine—glaucoma	0.000219	0.000726	CcSEcCtD
Ponatinib—Diarrhoea—Brinzolamide—glaucoma	0.000219	0.000726	CcSEcCtD
Ponatinib—Dry mouth—Betaxolol—glaucoma	0.000218	0.000723	CcSEcCtD
Ponatinib—Pruritus—Pilocarpine—glaucoma	0.000217	0.000722	CcSEcCtD
Ponatinib—Alopecia—Timolol—glaucoma	0.000217	0.00072	CcSEcCtD
Ponatinib—Mental disorder—Timolol—glaucoma	0.000215	0.000714	CcSEcCtD
Ponatinib—Dizziness—Dorzolamide—glaucoma	0.000215	0.000714	CcSEcCtD
Ponatinib—Rash—Brimonidine—glaucoma	0.000215	0.000713	CcSEcCtD
Ponatinib—Dermatitis—Brimonidine—glaucoma	0.000214	0.000712	CcSEcCtD
Ponatinib—Dizziness—Travoprost—glaucoma	0.000214	0.000711	CcSEcCtD
Ponatinib—Malnutrition—Timolol—glaucoma	0.000214	0.00071	CcSEcCtD
Ponatinib—Erythema—Timolol—glaucoma	0.000214	0.00071	CcSEcCtD
Ponatinib—Oedema—Betaxolol—glaucoma	0.000214	0.000709	CcSEcCtD
Ponatinib—Headache—Brimonidine—glaucoma	0.000213	0.000708	CcSEcCtD
Ponatinib—Decreased appetite—Clonidine—glaucoma	0.000213	0.000708	CcSEcCtD
Ponatinib—Infection—Betaxolol—glaucoma	0.000212	0.000704	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000212	0.000703	CcSEcCtD
Ponatinib—Fatigue—Clonidine—glaucoma	0.000212	0.000702	CcSEcCtD
Ponatinib—Dizziness—Brinzolamide—glaucoma	0.000211	0.000702	CcSEcCtD
Ponatinib—Nausea—Acetazolamide—glaucoma	0.000211	0.000699	CcSEcCtD
Ponatinib—Diarrhoea—Pilocarpine—glaucoma	0.00021	0.000698	CcSEcCtD
Ponatinib—Constipation—Clonidine—glaucoma	0.00021	0.000696	CcSEcCtD
Ponatinib—Pain—Clonidine—glaucoma	0.00021	0.000696	CcSEcCtD
Ponatinib—Nervous system disorder—Betaxolol—glaucoma	0.000209	0.000695	CcSEcCtD
Ponatinib—Thrombocytopenia—Betaxolol—glaucoma	0.000209	0.000694	CcSEcCtD
Ponatinib—Skin disorder—Betaxolol—glaucoma	0.000207	0.000689	CcSEcCtD
Ponatinib—Vomiting—Dorzolamide—glaucoma	0.000207	0.000686	CcSEcCtD
Ponatinib—Hyperhidrosis—Betaxolol—glaucoma	0.000206	0.000685	CcSEcCtD
Ponatinib—Rash—Dorzolamide—glaucoma	0.000205	0.000681	CcSEcCtD
Ponatinib—Dermatitis—Dorzolamide—glaucoma	0.000205	0.00068	CcSEcCtD
Ponatinib—Rash—Travoprost—glaucoma	0.000204	0.000678	CcSEcCtD
Ponatinib—Dermatitis—Travoprost—glaucoma	0.000204	0.000677	CcSEcCtD
Ponatinib—Headache—Dorzolamide—glaucoma	0.000204	0.000676	CcSEcCtD
Ponatinib—Vomiting—Brinzolamide—glaucoma	0.000203	0.000675	CcSEcCtD
Ponatinib—Dizziness—Pilocarpine—glaucoma	0.000203	0.000674	CcSEcCtD
Ponatinib—Headache—Travoprost—glaucoma	0.000203	0.000673	CcSEcCtD
Ponatinib—Nausea—Brimonidine—glaucoma	0.000202	0.000671	CcSEcCtD
Ponatinib—Rash—Brinzolamide—glaucoma	0.000202	0.000669	CcSEcCtD
Ponatinib—Vision blurred—Timolol—glaucoma	0.000201	0.000669	CcSEcCtD
Ponatinib—Dermatitis—Brinzolamide—glaucoma	0.000201	0.000668	CcSEcCtD
Ponatinib—Gastrointestinal pain—Clonidine—glaucoma	0.000201	0.000666	CcSEcCtD
Ponatinib—Headache—Brinzolamide—glaucoma	0.0002	0.000665	CcSEcCtD
Ponatinib—Vomiting—Pilocarpine—glaucoma	0.000195	0.000648	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000195	0.000646	CcSEcCtD
Ponatinib—Abdominal pain—Clonidine—glaucoma	0.000194	0.000644	CcSEcCtD
Ponatinib—Body temperature increased—Clonidine—glaucoma	0.000194	0.000644	CcSEcCtD
Ponatinib—Rash—Pilocarpine—glaucoma	0.000194	0.000643	CcSEcCtD
Ponatinib—Dermatitis—Pilocarpine—glaucoma	0.000194	0.000642	CcSEcCtD
Ponatinib—Insomnia—Betaxolol—glaucoma	0.000193	0.000641	CcSEcCtD
Ponatinib—Nausea—Dorzolamide—glaucoma	0.000193	0.000641	CcSEcCtD
Ponatinib—Headache—Pilocarpine—glaucoma	0.000192	0.000639	CcSEcCtD
Ponatinib—Nausea—Travoprost—glaucoma	0.000192	0.000638	CcSEcCtD
Ponatinib—Paraesthesia—Betaxolol—glaucoma	0.000192	0.000637	CcSEcCtD
Ponatinib—Dyspnoea—Betaxolol—glaucoma	0.00019	0.000632	CcSEcCtD
Ponatinib—Nausea—Brinzolamide—glaucoma	0.00019	0.00063	CcSEcCtD
Ponatinib—Dyspepsia—Betaxolol—glaucoma	0.000188	0.000624	CcSEcCtD
Ponatinib—Cough—Timolol—glaucoma	0.000187	0.000619	CcSEcCtD
Ponatinib—Decreased appetite—Betaxolol—glaucoma	0.000186	0.000616	CcSEcCtD
Ponatinib—Hypertension—Timolol—glaucoma	0.000185	0.000613	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000184	0.000612	CcSEcCtD
Ponatinib—Fatigue—Betaxolol—glaucoma	0.000184	0.000611	CcSEcCtD
Ponatinib—Constipation—Betaxolol—glaucoma	0.000183	0.000606	CcSEcCtD
Ponatinib—Pain—Betaxolol—glaucoma	0.000183	0.000606	CcSEcCtD
Ponatinib—Nausea—Pilocarpine—glaucoma	0.000182	0.000606	CcSEcCtD
Ponatinib—Myalgia—Timolol—glaucoma	0.000182	0.000604	CcSEcCtD
Ponatinib—Arthralgia—Timolol—glaucoma	0.000182	0.000604	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000181	0.0006	CcSEcCtD
Ponatinib—Dry mouth—Timolol—glaucoma	0.000178	0.000591	CcSEcCtD
Ponatinib—Asthenia—Clonidine—glaucoma	0.000176	0.000584	CcSEcCtD
Ponatinib—Oedema—Timolol—glaucoma	0.000174	0.000579	CcSEcCtD
Ponatinib—Pruritus—Clonidine—glaucoma	0.000174	0.000576	CcSEcCtD
Ponatinib—Infection—Timolol—glaucoma	0.000173	0.000575	CcSEcCtD
Ponatinib—Nervous system disorder—Timolol—glaucoma	0.000171	0.000568	CcSEcCtD
Ponatinib—Skin disorder—Timolol—glaucoma	0.000169	0.000563	CcSEcCtD
Ponatinib—Body temperature increased—Betaxolol—glaucoma	0.000169	0.000561	CcSEcCtD
Ponatinib—Hyperhidrosis—Timolol—glaucoma	0.000169	0.00056	CcSEcCtD
Ponatinib—Diarrhoea—Clonidine—glaucoma	0.000168	0.000557	CcSEcCtD
Ponatinib—Dizziness—Clonidine—glaucoma	0.000162	0.000539	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Timolol—glaucoma	0.000159	0.000528	CcSEcCtD
Ponatinib—Insomnia—Timolol—glaucoma	0.000158	0.000524	CcSEcCtD
Ponatinib—Paraesthesia—Timolol—glaucoma	0.000157	0.00052	CcSEcCtD
Ponatinib—Vomiting—Clonidine—glaucoma	0.000156	0.000518	CcSEcCtD
Ponatinib—Dyspnoea—Timolol—glaucoma	0.000156	0.000516	CcSEcCtD
Ponatinib—Rash—Clonidine—glaucoma	0.000155	0.000514	CcSEcCtD
Ponatinib—Dermatitis—Clonidine—glaucoma	0.000155	0.000513	CcSEcCtD
Ponatinib—Headache—Clonidine—glaucoma	0.000154	0.00051	CcSEcCtD
Ponatinib—Dyspepsia—Timolol—glaucoma	0.000154	0.00051	CcSEcCtD
Ponatinib—Asthenia—Betaxolol—glaucoma	0.000153	0.000509	CcSEcCtD
Ponatinib—Decreased appetite—Timolol—glaucoma	0.000152	0.000504	CcSEcCtD
Ponatinib—Pruritus—Betaxolol—glaucoma	0.000151	0.000502	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Timolol—glaucoma	0.000151	0.0005	CcSEcCtD
Ponatinib—Fatigue—Timolol—glaucoma	0.00015	0.000499	CcSEcCtD
Ponatinib—Pain—Timolol—glaucoma	0.000149	0.000495	CcSEcCtD
Ponatinib—Diarrhoea—Betaxolol—glaucoma	0.000146	0.000485	CcSEcCtD
Ponatinib—Nausea—Clonidine—glaucoma	0.000146	0.000484	CcSEcCtD
Ponatinib—Gastrointestinal pain—Timolol—glaucoma	0.000143	0.000474	CcSEcCtD
Ponatinib—Dizziness—Betaxolol—glaucoma	0.000141	0.000469	CcSEcCtD
Ponatinib—Abdominal pain—Timolol—glaucoma	0.000138	0.000458	CcSEcCtD
Ponatinib—Body temperature increased—Timolol—glaucoma	0.000138	0.000458	CcSEcCtD
Ponatinib—Vomiting—Betaxolol—glaucoma	0.000136	0.000451	CcSEcCtD
Ponatinib—Rash—Betaxolol—glaucoma	0.000135	0.000447	CcSEcCtD
Ponatinib—Dermatitis—Betaxolol—glaucoma	0.000135	0.000447	CcSEcCtD
Ponatinib—Headache—Betaxolol—glaucoma	0.000134	0.000444	CcSEcCtD
Ponatinib—Nausea—Betaxolol—glaucoma	0.000127	0.000421	CcSEcCtD
Ponatinib—Asthenia—Timolol—glaucoma	0.000125	0.000416	CcSEcCtD
Ponatinib—Pruritus—Timolol—glaucoma	0.000123	0.00041	CcSEcCtD
Ponatinib—Diarrhoea—Timolol—glaucoma	0.000119	0.000396	CcSEcCtD
Ponatinib—Dizziness—Timolol—glaucoma	0.000115	0.000383	CcSEcCtD
Ponatinib—Vomiting—Timolol—glaucoma	0.000111	0.000368	CcSEcCtD
Ponatinib—Rash—Timolol—glaucoma	0.00011	0.000365	CcSEcCtD
Ponatinib—Dermatitis—Timolol—glaucoma	0.00011	0.000365	CcSEcCtD
Ponatinib—Headache—Timolol—glaucoma	0.000109	0.000363	CcSEcCtD
Ponatinib—Nausea—Timolol—glaucoma	0.000104	0.000344	CcSEcCtD
Ponatinib—ABCB11—Metabolism—MTHFR—glaucoma	1.64e-05	6.41e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN2B—glaucoma	1.63e-05	6.38e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CAV1—glaucoma	1.63e-05	6.36e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SMO—glaucoma	1.62e-05	6.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—BAD—glaucoma	1.61e-05	6.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—BAD—glaucoma	1.6e-05	6.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN2B—glaucoma	1.59e-05	6.23e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EDN1—glaucoma	1.59e-05	6.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.58e-05	6.19e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EDN1—glaucoma	1.56e-05	6.12e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NGFR—glaucoma	1.55e-05	6.08e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FN1—glaucoma	1.55e-05	6.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN2B—glaucoma	1.55e-05	6.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN2B—glaucoma	1.54e-05	6.04e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TXN—glaucoma	1.54e-05	6.03e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ABCA1—glaucoma	1.53e-05	6e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CYP1B1—glaucoma	1.53e-05	6e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—BAD—glaucoma	1.53e-05	5.99e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MMP9—glaucoma	1.53e-05	5.99e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—BAD—glaucoma	1.53e-05	5.98e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—APOE—glaucoma	1.53e-05	5.97e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—BAD—glaucoma	1.52e-05	5.96e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CAV1—glaucoma	1.51e-05	5.92e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—CDKN1B—glaucoma	1.5e-05	5.87e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NTRK2—glaucoma	1.49e-05	5.81e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EDN1—glaucoma	1.48e-05	5.81e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EDN1—glaucoma	1.48e-05	5.79e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—glaucoma	1.48e-05	5.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NTRK1—glaucoma	1.48e-05	5.78e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—glaucoma	1.47e-05	5.77e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—glaucoma	1.47e-05	5.75e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NGF—glaucoma	1.46e-05	5.73e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1A—glaucoma	1.46e-05	5.7e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—C3—glaucoma	1.45e-05	5.66e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CDKN1B—glaucoma	1.44e-05	5.64e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NGF—glaucoma	1.44e-05	5.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SMO—glaucoma	1.44e-05	5.63e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NOS3—glaucoma	1.41e-05	5.52e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN2B—glaucoma	1.41e-05	5.52e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.41e-05	5.5e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP9—glaucoma	1.39e-05	5.45e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.39e-05	5.45e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—C3—glaucoma	1.39e-05	5.45e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—VEGFA—glaucoma	1.39e-05	5.42e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NOS3—glaucoma	1.39e-05	5.42e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL2L1—glaucoma	1.39e-05	5.42e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTT1—glaucoma	1.38e-05	5.4e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VEGFA—glaucoma	1.37e-05	5.38e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—C3—glaucoma	1.37e-05	5.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NGF—glaucoma	1.36e-05	5.34e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN2B—glaucoma	1.36e-05	5.33e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NOS3—glaucoma	1.36e-05	5.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NGF—glaucoma	1.36e-05	5.33e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.36e-05	5.31e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TXN—glaucoma	1.34e-05	5.25e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MTHFR—glaucoma	1.34e-05	5.23e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CDKN1B—glaucoma	1.33e-05	5.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NTRK2—glaucoma	1.32e-05	5.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EDN1—glaucoma	1.31e-05	5.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CDKN1B—glaucoma	1.3e-05	5.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—C3—glaucoma	1.3e-05	5.08e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—APOE—glaucoma	1.3e-05	5.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—C3—glaucoma	1.29e-05	5.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NOS3—glaucoma	1.29e-05	5.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NOS3—glaucoma	1.29e-05	5.04e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CAV1—glaucoma	1.28e-05	5.02e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CA1—glaucoma	1.28e-05	5.02e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—C3—glaucoma	1.28e-05	5.01e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—glaucoma	1.28e-05	5e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—CDKN1B—glaucoma	1.28e-05	5e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CDKN1B—glaucoma	1.28e-05	4.99e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGFR—glaucoma	1.27e-05	4.99e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—APOE—glaucoma	1.27e-05	4.98e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—glaucoma	1.27e-05	4.98e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTGS2—glaucoma	1.27e-05	4.96e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TXN—glaucoma	1.27e-05	4.95e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CAV1—glaucoma	1.26e-05	4.93e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BAD—glaucoma	1.26e-05	4.91e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—glaucoma	1.25e-05	4.9e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTGS2—glaucoma	1.25e-05	4.87e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—APOE—glaucoma	1.24e-05	4.87e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTSA—glaucoma	1.24e-05	4.86e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CAV1—glaucoma	1.23e-05	4.82e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NOS3—glaucoma	1.23e-05	4.81e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—glaucoma	1.23e-05	4.8e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GSTM1—glaucoma	1.23e-05	4.8e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2L1—glaucoma	1.23e-05	4.8e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CDKN1B—glaucoma	1.22e-05	4.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FN1—glaucoma	1.22e-05	4.78e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CDKN1B—glaucoma	1.21e-05	4.74e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NTRK1—glaucoma	1.21e-05	4.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CDKN1B—glaucoma	1.21e-05	4.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APOE—glaucoma	1.21e-05	4.72e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—BAD—glaucoma	1.21e-05	4.72e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APOE—glaucoma	1.2e-05	4.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CDKN1B—glaucoma	1.2e-05	4.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NGF—glaucoma	1.2e-05	4.7e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FN1—glaucoma	1.2e-05	4.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CAV1—glaucoma	1.2e-05	4.68e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.2e-05	4.68e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTT1—glaucoma	1.19e-05	4.67e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CAV1—glaucoma	1.19e-05	4.67e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—BAD—glaucoma	1.19e-05	4.64e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MTHFR—glaucoma	1.18e-05	4.63e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTGS2—glaucoma	1.18e-05	4.62e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—CDKN1B—glaucoma	1.18e-05	4.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—glaucoma	1.18e-05	4.61e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CA2—glaucoma	1.17e-05	4.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—BAD—glaucoma	1.16e-05	4.53e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—NOS3—glaucoma	1.14e-05	4.47e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—C3—glaucoma	1.14e-05	4.47e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FN1—glaucoma	1.14e-05	4.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FN1—glaucoma	1.14e-05	4.44e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MMP9—glaucoma	1.13e-05	4.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGFR—glaucoma	1.13e-05	4.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—BAD—glaucoma	1.13e-05	4.4e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—BAD—glaucoma	1.12e-05	4.39e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CDKN1B—glaucoma	1.12e-05	4.38e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CDKN1B—glaucoma	1.12e-05	4.37e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN2B—glaucoma	1.12e-05	4.37e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BAD—glaucoma	1.11e-05	4.35e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APOE—glaucoma	1.1e-05	4.31e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ABCA1—glaucoma	1.1e-05	4.3e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP1B1—glaucoma	1.1e-05	4.3e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CAV1—glaucoma	1.09e-05	4.27e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MTHFR—glaucoma	1.08e-05	4.24e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—glaucoma	1.07e-05	4.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NTRK1—glaucoma	1.07e-05	4.19e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EDN1—glaucoma	1.07e-05	4.19e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CDKN1B—glaucoma	1.07e-05	4.17e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CDKN1B—glaucoma	1.07e-05	4.17e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APOE—glaucoma	1.06e-05	4.16e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CDKN1B—glaucoma	1.06e-05	4.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CAV1—glaucoma	1.05e-05	4.12e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—glaucoma	1.05e-05	4.1e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—glaucoma	1.05e-05	4.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTT1—glaucoma	1.04e-05	4.07e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—glaucoma	1.04e-05	4.06e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—BAD—glaucoma	1.03e-05	4.01e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—glaucoma	1.02e-05	3.98e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—glaucoma	1.01e-05	3.95e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FN1—glaucoma	1e-05	3.92e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CAV1—glaucoma	1e-05	3.91e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—BAD—glaucoma	9.9e-06	3.87e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN2B—glaucoma	9.88e-06	3.87e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—glaucoma	9.86e-06	3.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGF—glaucoma	9.84e-06	3.85e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTT1—glaucoma	9.81e-06	3.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NOS3—glaucoma	9.71e-06	3.8e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	9.63e-06	3.77e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NOS3—glaucoma	9.53e-06	3.73e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCA1—glaucoma	9.52e-06	3.72e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1B1—glaucoma	9.52e-06	3.72e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EDN1—glaucoma	9.48e-06	3.71e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—C3—glaucoma	9.35e-06	3.66e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS3—glaucoma	9.32e-06	3.65e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—glaucoma	9.27e-06	3.63e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NOS3—glaucoma	9.05e-06	3.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NOS3—glaucoma	9.02e-06	3.53e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—glaucoma	8.86e-06	3.47e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTM1—glaucoma	8.79e-06	3.44e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CDKN1B—glaucoma	8.74e-06	3.42e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGF—glaucoma	8.71e-06	3.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—glaucoma	8.71e-06	3.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CAV1—glaucoma	8.63e-06	3.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—glaucoma	8.52e-06	3.33e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1B—glaucoma	8.41e-06	3.29e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ABCA1—glaucoma	8.29e-06	3.24e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1B1—glaucoma	8.29e-06	3.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—C3—glaucoma	8.28e-06	3.24e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TXN—glaucoma	8.27e-06	3.24e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1B—glaucoma	8.26e-06	3.23e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS3—glaucoma	8.25e-06	3.23e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FN1—glaucoma	8.21e-06	3.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BAD—glaucoma	8.12e-06	3.18e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1B—glaucoma	8.07e-06	3.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOS3—glaucoma	7.96e-06	3.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1B—glaucoma	7.84e-06	3.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1B—glaucoma	7.82e-06	3.06e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCA1—glaucoma	7.82e-06	3.06e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1B1—glaucoma	7.82e-06	3.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—glaucoma	7.79e-06	3.05e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—glaucoma	7.77e-06	3.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1B—glaucoma	7.74e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—glaucoma	7.71e-06	3.02e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—glaucoma	7.68e-06	3.01e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—glaucoma	7.65e-06	2.99e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CAV1—glaucoma	7.64e-06	2.99e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—glaucoma	7.61e-06	2.98e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—glaucoma	7.56e-06	2.96e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—glaucoma	7.54e-06	2.95e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FN1—glaucoma	7.27e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—glaucoma	7.26e-06	2.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—glaucoma	7.24e-06	2.83e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—glaucoma	7.23e-06	2.83e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BAD—glaucoma	7.18e-06	2.81e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAV1—glaucoma	7.16e-06	2.8e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1B—glaucoma	7.14e-06	2.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—glaucoma	6.99e-06	2.74e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—glaucoma	6.91e-06	2.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—glaucoma	6.9e-06	2.7e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—glaucoma	6.87e-06	2.69e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—glaucoma	6.73e-06	2.63e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—glaucoma	6.69e-06	2.62e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—glaucoma	6.63e-06	2.59e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—glaucoma	6.52e-06	2.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—glaucoma	6.52e-06	2.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—glaucoma	6.5e-06	2.54e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—glaucoma	6.41e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—glaucoma	6.39e-06	2.5e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—glaucoma	6.26e-06	2.45e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—glaucoma	6.25e-06	2.44e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—glaucoma	6.2e-06	2.43e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—glaucoma	5.86e-06	2.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—glaucoma	5.78e-06	2.26e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—glaucoma	5.73e-06	2.24e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—glaucoma	5.65e-06	2.21e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—glaucoma	5.52e-06	2.16e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—glaucoma	5.46e-06	2.13e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—glaucoma	5.42e-06	2.12e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—glaucoma	5.4e-06	2.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—glaucoma	5.28e-06	2.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—glaucoma	5.23e-06	2.05e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—glaucoma	5.19e-06	2.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—glaucoma	5.14e-06	2.01e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCA1—glaucoma	5.11e-06	2e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—glaucoma	5.11e-06	2e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—glaucoma	5.09e-06	1.99e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—glaucoma	5e-06	1.96e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—glaucoma	4.95e-06	1.94e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—glaucoma	4.93e-06	1.93e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—glaucoma	4.91e-06	1.92e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—glaucoma	4.7e-06	1.84e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—glaucoma	4.69e-06	1.84e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—glaucoma	4.63e-06	1.81e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—glaucoma	4.33e-06	1.7e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—glaucoma	4.29e-06	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—glaucoma	4.16e-06	1.63e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—glaucoma	4.09e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—glaucoma	4.08e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—glaucoma	3.85e-06	1.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—glaucoma	3.74e-06	1.46e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—glaucoma	3.61e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—glaucoma	3.55e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—glaucoma	3.52e-06	1.38e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—glaucoma	3.36e-06	1.31e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—glaucoma	3.33e-06	1.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—glaucoma	3.14e-06	1.23e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—glaucoma	2.52e-06	9.85e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—glaucoma	2.3e-06	9.01e-06	CbGpPWpGaD
